Home・Lista de Ações・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Fechado

SetorSaúde

192.57 5.65

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

181

Máximo

194

Indicadores-chave
By Trading Economics
Rendimento	-89M -454M
EPS	-2.29
Funcionários	883
EBITDA	-89M -437M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+10.23% upside

Dividendos
By Acuity
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	8.5B 40B
Abertura anterior	186.92
Fecho anterior	192.57

Sentimento de Notícias

By Acuity

67%

33%

291 / 340 Ranking em Healthcare

REVOLUTION Medicines Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 de jul. de 2026, 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 de jul. de 2026, 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 de jul. de 2026, 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 de jul. de 2026, 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 de jul. de 2026, 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 de jul. de 2026, 18:26 UTC

Social Media

News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 de jul. de 2026, 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

21 de jul. de 2026, 17:16 UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

20 de jul. de 2026, 17:31 UTC

Social Media

News

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.

Comparação entre Pares

Variação de preço

REVOLUTION Medicines Inc Previsão

Preço-alvo

By TipRanks

10.23% parte superior

Previsão para 12 meses

Média 201.12 USD 10.23%

Máximo 263 USD

Mínimo 151 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para REVOLUTION Medicines Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

Comprar

Manter

Vender

Com base em 19 analistas que deram avaliações de ações para REVOLUTION Medicines Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

291 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.